Bicycle Therapeutics PLC
bicycletherapeutics.comWhat Do They Do?
Develops synthetic peptide drug candidates for cancer and licenses its screening platform and drug programs to pharmaceutical companies.
10-K for FY2025, filed Mar 17, 2026We are a clinical-stage pharmaceutical company developing a novel class of medicines, which we refer to as Bicycle® molecules, for diseases…View ↗
Our internal programs are focused on oncology indications with high unmet medical need. Our product candidate, nuzefatide pevedotin…View ↗
Beyond our wholly owned oncology portfolio, we are collaborating with biopharmaceutical companies and organizations in additional…View ↗
The Company’s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The…View ↗
How Do They Make Money?
Pharmaceutical partners pay upfront license fees and may pay for research work as it is performed, option fees, development and regulatory milestones, and royalties if products reach sales.
10-K for FY2025, filed Mar 17, 2026The Company’s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The…View ↗
The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license…View ↗
Licenses of intellectual property: If a license to the Company’s intellectual property is determined to be distinct from the other promises…View ↗
Research and development services: The promises under the Company’s collaboration agreements may include research and development services…View ↗
Milestone payments: The Company’s collaboration agreements may include development and regulatory milestones. The Company evaluates whether…View ↗
$72.6M
-
10-K for FY2025, filed Mar 17, 2026
$72.6M ↗
Who Are Their Customers?
Pharmaceutical companies and biopharmaceutical organizations work with Bicycle through collaboration and license agreements for screening, research services and intellectual-property rights.
10-K for FY2025, filed Mar 17, 2026Beyond our wholly owned oncology portfolio, we are collaborating with biopharmaceutical companies and organizations in additional…View ↗
The Company’s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The…View ↗
Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised…View ↗
Do Revenues Turn Into Profits?
No. It lost $219M in FY2025.
10-K for FY2025, filed Mar 17, 2026
−$247.1MView ↗
10-K for FY2025, filed Mar 17, 2026
−$219MView ↗
10-K for FY2025, filed Mar 17, 2026
−$252MView ↗
How Are They Changing?
Growing. Revenue grew 6.2x in 4 years, from $11.7M in FY2021 to $72.6M in FY2025, about 58% a year.
Radiopharmaceutical programs
The older report describes toxin conjugates and immune-cell agonists among its internal candidates; the latest report also describes radioconjugates and imaging agents in its oncology pipeline.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 17, 2026Our product candidates, BT5528, BT8009, and BT1718, are each a Bicycle® Toxin Conjugate, or BTCTM. These Bicycles are chemically attached…View ↗
Our internal programs are focused on oncology indications with high unmet medical need. Our product candidate, nuzefatide pevedotin…View ↗
Who Do They Compete With?
Competes with Pfizer, Eli Lilly, Mabwell Therapeutics, Tianjin Conjustar Biologics, and Stemline Therapeutics
10-K for FY2025, filed Mar 17, 2026There are a number of currently marketed products and product candidates in preclinical research and clinical development by third parties…View ↗
Loading...
